NINLARO SUMMARY of Product Characteristics
NINLARO Patient information leaflet
NINLARO is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. NINLARO® has received a conditional marketing authorisation in Europe
Closing the efficacy and effectiveness gap – Presented at the 61st American Society of Hematology meeting
Prescribing Information and adverse event reporting details are available on this virtual stand.
NINLARO® has received a conditional marketing authorisation in Europe
This virtual stand was produced and fully funded by Takeda UK Ltd and is intended for healthcare professionals only.
© Takeda UK Limited, 2020. Registered office: 1 Kingdom Street, London, W2 6BD, United Kingdom.
Registered in England and Wales No. 3362860
C-APROM/UK/NINL/0007 Date of Preparation: October 2020